Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects

Trial Profile

Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Flecainide/modafinil (Primary) ; Modafinil
  • Indications Narcolepsy
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors Theranexus
  • Most Recent Events

    • 04 Oct 2016 According to a Theranexus media release, results from this study were recently presented in partnership with the French Armed Forces Biomedical Research Institute (IRBA), during the latest congress held by the European Sleep Research Society (ESRS 2016).
    • 17 May 2016 Results published in a Theranexus media release.
    • 17 May 2016 Primary endpoint (Vigilance levels) has been met, according to a Theranexus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top